Human papillomavirus types 6 and 11 (HPV-6 and HPV-11) are the major aetiological agents of condylomata acuminata. Serological studies of this disease have been difficult to perform and interpret because native, type-specific antigens have not been available. In particular, since these viruses have not been propagated in vitro and sufficient quantities of virions are not present in lesions, virus particles have been difficult to obtain. In the present study, we used HPV-11 particles, obtained from human tumours produced in athymic mice, as antigen in an ELISA to compare antibody responses between 46 patients with biopsyproven condylomata acuminata and 44 controls. The median [interquartile range] of the absorbance values for the condylomata acuminata and the control groups were respectively 0-324 [0-183, 1-029] and 0.118 [0-047, 0.286] (P= 0-0001). Thirty-three per cent of the absorbance values in the condylomata acuminata group were higher than any of those of the control group. Sera from patients whose biopsies contained the papillomavirus common antigen were more reactive than sera from patients whose biopsies did not contain it (P= 0-0014).This study demonstrates the presence of specific antibodies directed at native HPV-I 1 viral particles in the sera of patients with condylomata acuminata, and describes a test which can be used in future serological studies of this common sexually transmitted disease.
Introduction
Human anogenital warts (condylomata acuminata) are caused by distinct human papillomaviruses (HPV), mostly types 6 and 11 (Oriel, 1990) . These lesions are usually diagnosed accurately by careful physical examination. However, because of their small size or location, they may elude detection or proper identification (Oriel, 1990) . Supplemental diagnostic methods such as histology or cytology, with or without HPV nucleic acid detection, are useful but expensive and subject to sampling error. None of these techniques is practical for use in large surveys or in diagnosis of asymptomatic infection. Thus, the availability of an accurate serological test would greatly augment our ability to study the epidemiology, natural history, and response to treatment of anogenital warts. Early serological studies of condylomata acuminata patients used extracts of unspecified human warts as antigens in various immunoassays (Ogilvie, 1970; Nel & Fourie, 1973; Viac et al., 1977 Viac et al., , 1978 Pyrh6nen, 1978; Pyrh6nen et al., 1980) . At that time, the great diversity of HPV types was not appreciated, and results of these studies were highly 0001-0053 © 1991 SGM variable. Over 60 different HPV types have now been identified , each with a narrow epithelial tropism. There is generally no serological cross-reactivity between virions of different papillomavirus types (Gissmann et al., 1977; Orth et al., 1977 Orth et al., , 1978 Orth & Favre, 1985) . Indeed, in immunoassays using intact viral particles of HPV-1, the causative agent of plantar warts, plantar wart patients were more likely to have specific antibodies than controls (Kienzler et al., 1983; Anisimov~i et al., 1990; Steele & Gallimore, 1990; Viac et al., 1990) , whereas no difference in seroprevalence could be detected between controls and condylomata acuminata patients (Pfister & zur Hausen, 1978; Pfister et al., 1979; Kienzler et al., 1983; Viac et al., 1990) . The paucity of virions in most warts, including condylomata acuminata, and the inability to grow papillomaviruses in vitro, have limited the availability of suitable native antigens. The description by Kreider et al. (1985 Kreider et al. ( , 1987 of the athymic mouse HPV-11-infected human xenograft model has now provided investigators with a method for the production of HPV-11 viral particles. Using these particles in an ELISA, we detected specific antibodies in sera of patients with documented condylomata acuminata.
I4I. Bonnez and others

Methods
HPV-11 purification. Fragments of human neonatal foreskins were infected with an HPV-11 viral suspension and placed under the renal capsule of nu/nu athymic mice according to the protocol described by Kreider et al. (1985 Kreider et al. ( , 1987 . The resulting tumours were collected several months later, pooled, and HPV-11 virions were purified by a series of high-speed and caesium chloride centrifugations, according to the protocol described by Favre et al. (1975) , but omitting trypsin treatment and the final sucrose gradient centrifugation. Full viral particles were identified by electron microscopy after staining with 2 neutral buffered phosphotungstic acid. By the same technique, viral particles were counted after mixing with 109 nm polystyrene latex beads (Ladd Research Industries) (Miller, 1974) . The protein content of the preparation was determined by comparative densitometry of Coomassie blue-stained bands on polyacrylamide gels, using bovine serum albumin as a standard and the major capsid protein of HPV-11 for the measurement.
Patient populations. Sera from three groups of patients were tested. Group I consisted of 27 volunteer nuns and priests who upon answering a detailed questionnaire denied any lifetime sexual activity or genital warts; our aim was to have individuals with a low likelihood not only of genital HPV-6 or -11 disease, but also of asymptomatic infection with these viruses. The group's age (mean +__ s.D., in years) was 49-6 _ 11-7. Group 2 consisted of 17 additional volunteers with clinically documented cutaneous warts, but no history, relating to themselves or their partners, of HPV genital infection. This group was chosen to assess potential serological cross-reactivity between HPV-11 on one hand, and HPV-1 and -2, the aetiological agents of these most common HPV diseases, on the other hand. The group's age was 22.8 + 4.4. Subjects had hand (29~), plantar (59~) or both (12~) warts. Group 3 included 46 patients, age 24.6 + 5.2, with biopsy-proven external condylomata acuminata (Table 1 ). In 41 biopsy specimens, HPV typing was done by Southern blot and/or in situ hybridization, according to techniques already described . Thirty-two specimens contained HPV-6, six contained HPV-II, and in three biopsies, HPV nucleic acids were not detected. The common papillomavirus antigen (Jenson et al., 1980) was present in 17 of 35 biopsy samples, when assayed by immunocytochemistry (Wilbur et al., 1988) .
ELISA. The immunoassay was carried out in 96-well Maxisorp polystyrene plates (Nunc-Vanguard International). One-hundred microlitres of HPV-11 viral suspension (0.8 ng of protein/~tl, or approximately 225 x 106 particles/~tl), diluted in carbonate buffer (Voller et aL, 1976) , was dispensed in alternate test wells; the remaining wells (controls) were filled with buffer without antigen. After incubation overnight at 4 °C in a humid chamber, plates were washed three times with PBS-Tween (Voller et al., 1976) dispensed with a manual washer (Immunowash 12, Nunc) . Duplicate serum samples were tested in a volume of 100 ~tl/well, at a 1 : 20 dilution in Blotto buffer (Johnson et al., 1984) . After a 90 min incubation at 37 °C in a humid chamber, plates were washed, and 100 Ixl of a 10 -3 dilution in Blotto buffer of an affinity-purified goat anti-human IgG gamma chain antibody conjugated to alkaline phosphatase (Tago) was added to each well. Plates were incubated for 90 min at 37 °C in a humid chamber, washed, and the substrate p-nitrophenol phosphate (Sigma) in diethanolamine buffer (Voller et al., 1976) was added (200 Ixl/well) to all wells plus a blank well. Incubation was carried out at room temperature for 20 min before interruption by the addition of 50 p.1/well of 3 MNaOH. Plates were immediately read in an automated ELISA plate reader at 405 nm. For each serum, the absorbance values of the control wells were subtracted from the values of the test wells, and the mean was calculated. The intra-and inter-assay coefficients of variation were calculated by testing a reactive serum sample 12 times in duplicate, in plates prepared and used on separate days (Rodbard, 1974) . The MannWhitney U test was used for all statistical comparisons, and a twotailed P value of less than 0.05 was considered statistically significant.
Results
Fig. 1 displays the absorbance values observed with the sera from the three groups of patients. There was no significant difference between groups 1 and 2 (P = 0.78); thus, these patients were combined into a single control group. The median [interquartile range] of the absorbance values for the control group and group 3 were respectively 0.118 [0.048, 0-286] and 0-324 [0.183, 1.029], a statistically significant difference (P = 0.0001). Taking the highest absorbance value of the control group (i.e. 476) as a cut-off (that is, assigning to the test a specificity of 100~), the sensitivity of the assay was 32.6~ (15/46). Assay performance was also evaluated by determination of the intra-and inter-assay coefficients of variation, which were 8~ and 6.4~, respectively.
To analyse further the serological reactivity of patients with condylomata acuminata, we examined the results according to the presence or absence of the common papillomavirus antigen in wart biopsies (Fig. 2) 
Discussion
Using HPV-11 viral particles as antigen in an ELISA we demonstrated that the sera of condylomata acuminata patients have greater reactivities than sera from controls with or without non-genital warts. Since most of the patients were infected with HPV-6, and because no difference in seroreactivity according to type was observed, we assume that there is antigenic crossreactivity between HPV-6 and HPV-11 virions, an observation supported by the close, 85 ~o, DNA sequence similarity between these two viruses (Chow et al., 1987) . Previous studies have documented cross-reactivity of human antibodies for HPV-6b and HPV-11 fusion proteins derived from the LI open reading frame, which encodes the major capsid protein (Jenison et al., 1989 (Jenison et al., , 1990 . In addition to demonstrating seroreactivity among infected patients, we also observed a strong relationship between the presence of the common papillomavirus antigen in wart biopsies and seroreactivity to HPV-I 1 particles. This observation supports the specific nature of the serological response measured by the ELISA, inasmuch as patients who are exposed to detectable quantities of capsid protein antigens would be expected to develop a more vigorous humoral response to intact virions than patients not exposed to these antigens. One should also note that most of the sera we used in this assay had been previously tested against various HPV-6 recombinant fusion proteins; no spurious differences in seroreactivity were then observed between control and patient sera (Strike et al., 1989; Bonnez et al., 1990) . The antigenic specificity of HPV-1 ! viral particles that is apparent in our observation is not surprising: HPV-I virions have the same specificity also (Kienzler et , 1983; Anisimov~t et al., 1990; Steele & Gallimore, 1990; Viac et al., 1990) . However, the limits and mechanisms of the antigenic specificity of viral particles of different HPV types will have to be more precisely defined. This is the first report of an immunoassay capable of detecting HPV type 6-and 11-specific antibodies in sera of patients with biopsy-proven condylomata acuminata.
Other immunoassays, using recombinant or synthetic HPV-6b-derived antigens have been reported, but have not demonstrated a difference in specific seroreactivity between control groups and patients with documented HPV-6 or -11 infection. In a previous study, we used Western blotting to assay sera from condylomata acuminata patients for reactivity to each of seven flgalactosidase fusion proteins derived from contiguous fragments of the L1 and L2 open reading frames (ORFs) of HPV-6b (Strike et al., 1989) . We were unable to find specific antibodies. Jenison et al. (1989 Jenison et al. ( , 1990 used an HPV-6b Ll-derived synthetic peptide in an ELISA, as well as TrpE fusion proteins originating from the E2, E7, L1 and L20RFs in a Western blot assay to detect specific antibodies in a sexually transmitted diseases clinic population. Surprisingly, the seroprevalence profile in that group was similar to the one in a control group of children. These authors speculated that this observation may reflect frequent infection with HPV-6 early in life. Using an HPV-6b L1 TrpE fusion protein encompassing the amino acid sequence of the synthetic peptide of Jenison et al. (1989) , we tested the sera of condylomata acuminata patients and found a seroprevalence rate of about 50~ . As in the observations of the previous investigators, this rate did not differ significantly from that of controls with no history of sexual activity. A preliminary report of a Western blot assay using an HPV-6b L1 clI fusion protein, indicated a higher seroprevalence in colposcopy clinic patients than in children (Li et al., 1987) . However, these results were not correlated with HPV type or disease status. Other investigators utilized denatured bovine papillomavirus (BPV) type 2 in ELISA and detected antibodies among condylomata acuminata patients with an overall accuracy up to 99~ (Baird, 1983; Beiss et al., 1987) . As denatured BPV exhibits a broadly cross-reactive papillomavirus antigen (Jenson et al., 1980) , the specificity of these immunoassays for condylomata acuminata is surprising, and we have not been able to replicate these results (unpublished data).
The present work does not elucidate the nature of the epitopes responsible for immunological reactivity. The HPV-11 virions used in the assay appeared as full viral particles under electron microscopy. Therefore, conformational as well as non-conformational epitopes could be involved. 'Generally, recombinant fusion proteins, when used in immunoassays, have been unable to permit the distinction between condyloma acuminatum patient and control sera; therefore, we are inclined to believe that fragile conformational epitopes are required for specific immunological reactivity. It should be noted for instance, that an epitope overlapping two distinct capsid proteins would not be duplicated by a single recombinant viral protein, however faithful it might be to the native conformation.
The relative insensitivity of our assay is possibly the reflection of factors related to the assay methodology and the immunopathogenesis of infection. The limited availability of the antigen has precluded the optimization of the reaction conditions. However our limited experience in this regard indeed suggests that higher concentrations of antigen would result in greater sensitivity, specificity being equal. Nonetheless, one has to consider the possibility that not all patients infected by HPV-6 or -11 mount a specific antibody response, or that this response is not stable over the course of the infection. These and other issues are the matter of future investigations.
The difficulty and high cost associated with producing HPV-11 particles in athymic mice, along with the relatively low sensitivity of the test as currently used, make widespread use of our ELISA impractical at the present time. However the test can be used to conduct small-scale seroprevalence studies, and also can be used in other well defined settings. In addition, the assay could serve as a reference for the development of cheaper and more convenient immunoassays for the diagnosis of HPV-11-induced disease. In addition to demonstrating the feasibility of developing a specific serological test, our observations provide the best currently available evidence that patients with biopsy-proven condylomata acuminata possess serum antibodies directed against type-specific genital tract HPV antigens, and that control subjects without anogenital warts do not.
